Brokerages expect that Natera Inc (NASDAQ:NTRA) will report sales of $66.23 million for the current fiscal quarter, according to Zacks. Three analysts have made estimates for Natera’s earnings, with the lowest sales estimate coming in at $65.50 million and the highest estimate coming in at $67.25 million. Natera posted sales of $56.66 million in the same quarter last year, which suggests a positive year-over-year growth rate of 16.9%. The company is scheduled to announce its next quarterly earnings results on Wednesday, November 14th.

According to Zacks, analysts expect that Natera will report full year sales of $263.08 million for the current year, with estimates ranging from $259.50 million to $266.93 million. For the next year, analysts anticipate that the firm will post sales of $330.80 million, with estimates ranging from $310.00 million to $350.95 million. Zacks Investment Research’s sales averages are a mean average based on a survey of sell-side analysts that cover Natera.

Natera (NASDAQ:NTRA) last issued its quarterly earnings data on Wednesday, August 8th. The medical research company reported ($0.55) earnings per share for the quarter, hitting the Zacks’ consensus estimate of ($0.55). Natera had a negative net margin of 59.07% and a negative return on equity of 752.93%. The business had revenue of $63.07 million during the quarter, compared to analysts’ expectations of $61.71 million. During the same period in the previous year, the company earned ($0.55) earnings per share. Natera’s revenue for the quarter was up 20.6% on a year-over-year basis.

NTRA has been the subject of a number of analyst reports. Morgan Stanley boosted their price objective on shares of Natera from $21.00 to $41.00 and gave the stock an “overweight” rating in a research note on Friday, September 28th. Canaccord Genuity boosted their price objective on shares of Natera from $25.00 to $29.00 and gave the stock a “buy” rating in a research note on Thursday, August 16th. JPMorgan Chase & Co. initiated coverage on shares of Natera in a research note on Friday. They issued a “neutral” rating and a $26.00 price objective for the company. Zacks Investment Research upgraded shares of Natera from a “sell” rating to a “hold” rating in a research note on Thursday, June 21st. Finally, Robert W. Baird boosted their price objective on shares of Natera from $17.00 to $20.00 and gave the stock an “outperform” rating in a research note on Thursday, June 28th. One analyst has rated the stock with a sell rating, two have issued a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company. Natera has an average rating of “Buy” and a consensus target price of $26.13.

Shares of Natera stock traded down $1.76 on Monday, reaching $21.64. The stock had a trading volume of 836,426 shares, compared to its average volume of 413,280. The company has a current ratio of 1.69, a quick ratio of 1.56 and a debt-to-equity ratio of -3.32. Natera has a fifty-two week low of $8.60 and a fifty-two week high of $29.62. The stock has a market capitalization of $1.46 billion, a price-to-earnings ratio of -9.02 and a beta of 2.24.

In related news, COO Steven Leonard Chapman sold 35,000 shares of the business’s stock in a transaction on Tuesday, October 2nd. The shares were sold at an average price of $23.76, for a total transaction of $831,600.00. Following the transaction, the chief operating officer now owns 19,022 shares of the company’s stock, valued at $451,962.72. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Matthew Rabinowitz sold 324,844 shares of the business’s stock in a transaction on Wednesday, September 26th. The stock was sold at an average price of $24.85, for a total transaction of $8,072,373.40. Following the transaction, the chief executive officer now directly owns 982,442 shares in the company, valued at approximately $24,413,683.70. The disclosure for this sale can be found here. Insiders have sold 1,813,321 shares of company stock worth $44,508,270 in the last ninety days. 13.18% of the stock is currently owned by insiders.

A number of hedge funds have recently made changes to their positions in the stock. Northern Trust Corp increased its position in Natera by 1.5% during the first quarter. Northern Trust Corp now owns 375,674 shares of the medical research company’s stock worth $3,483,000 after acquiring an additional 5,428 shares during the period. Swiss National Bank increased its holdings in Natera by 13.2% in the 1st quarter. Swiss National Bank now owns 47,900 shares of the medical research company’s stock valued at $444,000 after buying an additional 5,600 shares during the period. State of Wisconsin Investment Board increased its holdings in Natera by 30.4% in the 2nd quarter. State of Wisconsin Investment Board now owns 30,000 shares of the medical research company’s stock valued at $565,000 after buying an additional 7,000 shares during the period. Trexquant Investment LP increased its holdings in Natera by 76.6% in the 2nd quarter. Trexquant Investment LP now owns 22,643 shares of the medical research company’s stock valued at $426,000 after buying an additional 9,820 shares during the period. Finally, State Board of Administration of Florida Retirement System bought a new stake in Natera in the 2nd quarter valued at $200,000. 66.31% of the stock is currently owned by institutional investors and hedge funds.

About Natera

Natera, Inc, a diagnostics company, provides preconception and prenatal genetic testing services. It primarily offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases that could be passed on to the carrier's children; and Spectrum pre-implantation genetic screening and Spectrum pre-implantation genetic diagnosis to analyze chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle.

Read More: Understanding Compound Annual Growth Rate (CAGR)

Get a free copy of the Zacks research report on Natera (NTRA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Natera (NASDAQ:NTRA)

Receive News & Ratings for Natera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natera and related companies with MarketBeat.com's FREE daily email newsletter.